SCHEMBL24129342

SCHEMBL24129342

Cc1c(Br)cc(C(=O)Cl)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 4/20 0.39
TTR P02766 1/20 0.38
ALDH1A1 P00352 3/20 0.35
HPGD P15428 4/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TSHR P16473 2/20 0.33
GSK3B P49841 1/20 0.33
TPMT P51580 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
APOBEC3A P31941 1/20 0.32
HTT P42858 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30601660 0.86 HDAC1 (0.48) ACP1TTRALDH1A1HPGDGAA
SCHEMBL26626630 0.86 HDAC1 (0.48) ACP1TTRALDH1A1HPGDGAA
SCHEMBL11818428 0.80 APEX1 (0.41) TTRALDH1A1TSHRGSK3BTPMT
SCHEMBL27101413 0.78 CA5A (0.48) ACP1TTRALDH1A1HPGDGAA
SCHEMBL1191845 0.78 TTR (0.62) TTRALDH1A1HPGDMEN1KMT2A
SCHEMBL11731338 0.78 TTR (0.39) TTRALDH1A1TSHRGSK3BTPMT
SCHEMBL1071876 0.78 TTR (0.62) ACP1TTRALDH1A1HPGDKMT2A
SCHEMBL7084456 0.76 GSK3B (0.57) TTRALDH1A1GAATSHRGSK3B
SCHEMBL987177 0.76 TTR (0.38) TTRALDH1A1HPGDTSHRGSK3B
SCHEMBL1003817 0.76 TSHR (0.53) ACP1TTRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606566-B2 Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) 2026-04-21 US disclosed
US-20240067659-A1 METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND JW PHARMACEUTICAL CORPORATION (KR) 2024-02-29 US disclosed
US-20230348471-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 US disclosed
US-20230348471-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 US disclosed
US-20230348471-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 US disclosed
CN-115715291-A Bruton's tyrosine kinase inhibitor and preparation method thereof 上海华汇拓医药科技有限公司 2023-02-24 CN disclosed
WO-2021254483-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR 上海华汇拓医药科技有限公司 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606566-B2 Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors BTK, LYN, SYK ACP1 18/4885TTR 2752/4885ALDH1A1 4530/4885
US-20230348471-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR BTK, SYK, LCK ACP1 182/4885TTR 4665/4885ALDH1A1 4598/4885
US-20240067659-A1 METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND REN, NOD1, NLRP3 ACP1 2866/4885TTR 1146/4885ALDH1A1 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.